GlaxoSmithKline Balance Sheet Analysis From 2010 to 2024
GSK Stock | USD 40.86 0.38 0.92% |
GlaxoSmithKline |
Most indicators from GlaxoSmithKline PLC's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into GlaxoSmithKline PLC ADR current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out GlaxoSmithKline PLC Valuation and GlaxoSmithKline PLC Correlation analysis. At this time, GlaxoSmithKline PLC's Selling General Administrative is quite stable compared to the past year. Discontinued Operations is expected to rise to about 12.7 B this year, although Enterprise Value Over EBITDA will most likely fall to 7.90.
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 784M | 879M | 775M | 502.2M | Depreciation And Amortization | 2.6B | 2.4B | 2.3B | 1.2B |
GlaxoSmithKline PLC fundamental ratios Correlations
Click cells to compare fundamentals
GlaxoSmithKline PLC Account Relationship Matchups
High Positive Relationship
High Negative Relationship
GlaxoSmithKline PLC fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 79.7B | 80.4B | 79.1B | 60.1B | 59.0B | 32.8B | |
Other Current Liab | 755M | 765M | 958M | 2.3B | 14.3B | 15.0B | |
Net Debt | 25.8B | 20.9B | 19.9B | 17.3B | 15.1B | 8.3B | |
Accounts Payable | 14.9B | 15.8B | 17.6B | 16.3B | 3.7B | 6.2B | |
Cash | 4.7B | 6.3B | 4.3B | 3.7B | 2.9B | 2.7B | |
Inventory | 5.9B | 6.0B | 5.8B | 5.1B | 5.5B | 3.0B | |
Total Liab | 61.3B | 59.6B | 57.8B | 50.1B | 46.2B | 25.5B | |
Total Current Assets | 19.5B | 20.2B | 18.7B | 20.8B | 18.6B | 11.9B | |
Capital Stock | 1.3B | 1.3B | 1.3B | 1.3B | 1.3B | 1.3B | |
Short Term Debt | 6.9B | 3.7B | 3.6B | 4.0B | 2.8B | 2.2B | |
Common Stock | 1.3B | 1.3B | 1.3B | 1.3B | 1.3B | 1.3B | |
Retained Earnings | 5.1B | 6.8B | 7.9B | 4.4B | 7.2B | 7.6B | |
Intangible Assets | 31.0B | 29.8B | 30.1B | 14.3B | 14.8B | 11.4B | |
Other Liab | 13.7B | 14.1B | 13.5B | 10.2B | 11.7B | 14.2B | |
Long Term Debt | 22.6B | 23.4B | 20.6B | 17.0B | 14.2B | 17.5B | |
Good Will | 10.6B | 10.6B | 10.6B | 7.0B | 6.8B | 5.3B | |
Other Current Assets | 1.6B | 617M | 525M | 7.7B | 561M | 533.0M | |
Other Assets | 5.1B | 5.3B | 6.9B | 6.9B | 7.9B | 5.4B | |
Net Receivables | 7.1B | 7.3B | 8.0B | 7.1B | 7.4B | 6.5B | |
Net Tangible Assets | (30.1B) | (25.8B) | (25.6B) | (10.8B) | (12.4B) | (13.0B) | |
Short Long Term Debt | 6.7B | 3.5B | 3.4B | 3.8B | 2.7B | 4.3B |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out GlaxoSmithKline PLC Valuation and GlaxoSmithKline PLC Correlation analysis. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Complementary Tools for GlaxoSmithKline Stock analysis
When running GlaxoSmithKline PLC's price analysis, check to measure GlaxoSmithKline PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GlaxoSmithKline PLC is operating at the current time. Most of GlaxoSmithKline PLC's value examination focuses on studying past and present price action to predict the probability of GlaxoSmithKline PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GlaxoSmithKline PLC's price. Additionally, you may evaluate how the addition of GlaxoSmithKline PLC to your portfolios can decrease your overall portfolio volatility.
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |
Is GlaxoSmithKline PLC's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.77) | Dividend Share 0.58 | Earnings Share 2.97 | Revenue Per Share 14.97 | Quarterly Revenue Growth 0.092 |
The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.